| Objective: To offer credible basis of evidence-based medicine for normative and optimized clinical therapeutic schedule with a systematic review about recombinant human growth hormone(rh GH)for idiopathic short stature(ISS)and relationship between therapeutic effect and dose.Methods: Searching randomized clinical trials from 1985 to 2015,thatrh GH treaments for ISS from EMBASE,PUBMED,Cochrane Library,MEDLINE,OVID and CBM,CNKI,VIP.And also searching important academic conference,data and abstract from media artificially with keywords :recombinant human growth hormone,idiopathic short stature andtreatment.According Cochrane handbook, screening data drawing data and assessing researchs by two commentators.Make meta system with Revman5.3,definitively.Results: Fitting into 18 RCTS,which cover 1094 ISS children,the experimental group included 601 cases, the control group included 493 cases.The result of meta system shows: one year after treatment, GV of the experimental exceeds that of the control obviously[MD= 3.57cm/y,95%CI(2.63,4.51),P<0.00001]; and Ht SDS of the experimental exceeds that of the control obviously [ MD=0.42 SDS,95%CI(0.28,0.57),P<0.00001]; adult Ht SDS of the experimental exceeds that of the control obviously[MD=0.58 SDS,95%CI(0.32,0.84),P<0.00001].adult Ht SDS for dosage of 0.067mg/kg/day exceeds that for dosage of 0.033mg/kg/day. Conclusion:1?The rh Gh treatment for ISS children can improve GV obviously, and enhance final adult height possibility.2?The effects of rh GH treatment for ISS children are positively correlated with drug dosage. |
PDF Full Text Request